Effect Of Adding Ublituximab To Ibrutinib On Pfs, Orr, And Mrd Negativity In Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results Of The Genuine Phase Iii Study.Jeff P. Sharman,Danielle M. Brander,Anthony R. Mato,Nilanjan Ghosh,Stephen J. Schuster,Suman Kambhampati,John M. Burke,Frederick Lansigan,Marshall T. Schreeder,Scott D Lunin,Alexander Zweibach,Mikhail Shtivelband,Patrick M. Travis,Jason Claud Chandler,Kathryn S. Kolibaba,Peter Sportelli,Hari P. Miskin,Michael S. Weiss,Ian FlinnJOURNAL OF CLINICAL ONCOLOGY（2020）引用 10|浏览65暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
